Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Rhea-AI Summary

Lumos Pharma, Inc. (LUMO) to Host Webinar on December 6, 2023 to Discuss Phase 2 OraGrowtH210 and OraGrowtH212 Trials Results with Esteemed Thought Leaders

Webinar to be Held December 6, 2023 at 1:30pm EST

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in the field of endocrinology:

• Andrew Dauber, MD, Chief of Endocrinology at Children's National Medical Center, Washington, D.C.
• Fernando Cassorla, MD, Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research, University of Chile
• Leslie A. Soyka, MD, Chief of Pediatric Endocrinology, UMass Memorial Medical Center; Associate Professor, UMass Chan Medical School, Worcester, MA
  

Virtual KOL Event: Review of Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency Wednesday, December 6, 2023 | 1:30 PM EST

To register for the virtual KOL Event, please click through the link here.

About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

FAQ

What is the date of the webinar hosted by Lumos Pharma, Inc. (LUMO)?

The webinar will be held on December 6, 2023 at 1:30 PM EST.

What is the purpose of the webinar hosted by Lumos Pharma, Inc. (LUMO)?

The purpose of the webinar is to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.

Who will be joining the management at the webinar hosted by Lumos Pharma, Inc. (LUMO)?

Three esteemed thought leaders in the field of endocrinology, including Andrew Dauber, MD, Fernando Cassorla, MD, and Leslie A. Soyka, MD, will be joining the management.

What is the treatment potential being discussed at the webinar hosted by Lumos Pharma, Inc. (LUMO)?

The treatment potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency will be discussed at the webinar.

How can one register for the virtual KOL Event hosted by Lumos Pharma, Inc. (LUMO)?

To register for the virtual KOL Event, please click through the link provided in the press release.